SCHEMBL9275485

SCHEMBL9275485

COc1cn(C2CCCC2)c2cc(NC3CCCCC3)c(F)c(F)c2c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOXO1 Q12778 1/20 0.42
GAA P10253 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
GSK3B P49841 1/20 0.37
NPSR1 Q6W5P4 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTT P42858 4/20 0.36
PDGFRB P09619 2/20 0.36
PDGFRA P16234 2/20 0.36
ALDH1A1 P00352 7/20 0.35
KDM4E B2RXH2 6/20 0.35
TSHR P16473 5/20 0.35
MAPK1 P28482 5/20 0.35
HSD17B10 Q99714 5/20 0.35
HPGD P15428 3/20 0.35
USP2 O75604 2/20 0.35
ALOX15 P16050 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265596 0.84 FOXO1 (0.45) FOXO1GAAKMT2AMEN1GSK3B
SCHEMBL265562 0.83 GAA (0.48) FOXO1GAAKMT2AMEN1NPSR1
SCHEMBL263816 0.81 FOXO1 (0.60) FOXO1GAAKMT2AMEN1GSK3B
SCHEMBL9278373 0.74 AR (0.40) KMT2AMEN1PDGFRBPDGFRAALDH1A1
SCHEMBL266982 0.72 MEN1 (0.46) FOXO1GAAKMT2AMEN1GSK3B
SCHEMBL27743195 0.71 MEN1 (0.52) FOXO1GAAKMT2AMEN1GSK3B
SCHEMBL14248104 0.70 MEN1 (0.49) FOXO1GAAKMT2AMEN1HTT
SCHEMBL14248443 0.70 MEN1 (0.48) FOXO1GAAKMT2AMEN1GSK3B
SCHEMBL14248318 0.70 MEN1 (0.46) FOXO1GAAKMT2AMEN1GSK3B
SCHEMBL262114 0.69 MEN1 (0.53) FOXO1GAAKMT2AMEN1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629126-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC. (JP) 2014-01-14 US disclosed
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY10, P2RY12, P2RY11 FOXO1 1911/4885GAA 4203/4885KMT2A 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.